Prostate cancer screening. What family physicians believe is best

1995 ◽  
Vol 4 (4) ◽  
pp. 317-322 ◽  
Author(s):  
R. J. Hicks
2017 ◽  
Vol 12 (2) ◽  
pp. E53-8 ◽  
Author(s):  
Jason Paul Akerman ◽  
Christopher B. Allard ◽  
Camilla Tajzler ◽  
Anil Kapoor

Introduction: This study serves as an update of prostate cancer screening practices among family physicians in Ontario, Canada. Since this population was first surveyed in 2010, the Canadian Task Force on Preventive Health Care (CTFPHC) and the United States Preventive Services Task Force (USPSTF) released recommendations against prostate cancer screening.Methods: An online survey was developed through input from urologists and family practitioners. It was distributed via email to all members of the Ontario Medical Association’s Section on General and Family practice (11 657 family physicians). A reminder email was sent at two weeks and the survey remained active for one month.Results: A total of 1880 family physicians completed surveys (response rate 16.1%). Overall, 80.4% offered prostate cancer screening compared to 91.7% when surveyed in 2010. Physicians new to practice (two years or less) were the most likely to not offer screening (24.6%). A combination of digital rectal exam (DRE) and prostate-specific antigen (PSA) remained the most common form of screening (58.3%). Following the release of the CTFPHC recommendations, 45.6% of respondents said they now screen fewer patients. Participants were less familiar with national urological society guidelines compared to task force recommendations. The majority (72.6%) of respondents feel PSA screening leads to overdiagnosis and treatment. Those surveyed remained split with respect to PSA utility.Conclusions: Data suggest a decline in screening practices since 2010, with newer graduates less likely to offer screening. CFTPHC and USPSTF recommendations had the greatest impact on clinical practice. Those surveyed were divided with respect to PSA utility. Some additional considerations to PSA screening in the primary care setting, including patient-driven factors, were not captured by our concise survey.


2012 ◽  
Vol 6 (3) ◽  
pp. 188-193 ◽  
Author(s):  
Christopher B. Allard ◽  
Shawn Dason ◽  
Janis Lusis ◽  
Anil Kapoor

2013 ◽  
Vol 6 (3) ◽  
pp. 188-93
Author(s):  
Christopher B. Allard ◽  
Shawn Dason ◽  
Janis Lusis ◽  
Anil Kapoor

Introduction: The utility of prostate cancer screening is controversial. We sought to determine whether Ontario’s family physicians believe it is beneficial and to characterize their screening protocols.Methods: A survey was developed with input from urologists,family physicians and the Ontario Medical Association’s Sectionon General and Family Practice. Questions covered three domains: (1) demographics, (2) beliefs about screening utility and (3) screening practices. All 7302 family physicians in Ontario were invited by email to complete the online survey.Results: A total of 969 physicians completed the survey; 955(52.0% male, 48.0% female) were included. Most (80.97%) useprostate-specific antigen (PSA) and digital rectal examination (DRE) for screening; 9.4% use DRE alone and 7.15% PSA. Of the respondents, 8.3% do not offer prostate cancer screening. Most physicians begin offering screening at age 50 (72.9%) and stop at ages 70 or 80 (68.4%); 17.9% offer lifelong screening. In response to the statement “screening with DRE provides a survival benefit,” 37.6% and 32.6 agreed and disagreed, respectively. For “screening with PSA provides a survival benefit,” 43.3% agreed and 31.0% disagreed. For the statement “the benefits of prostate cancer screening outweigh the risks,” 51.4% agreed and 22.0% disagreed.Discussion: Although 91.7% of respondents offer prostate cancer screening, they are divided over its utility. Only 51.4% were convinced that the benefits outweighed the harms. There is significant variability between physicians’ screening protocols. A limitation of study is the possibility of selection bias. Nevertheless, this is the largest sample of Ontario family physicians ever surveyed about prostate cancer screening and highlights divergent physician practices and a need for more conclusive evidence on screening utility.


2022 ◽  
Vol 54 (1) ◽  
pp. 30-37
Author(s):  
Nicholas Shungu ◽  
Vanessa A. Diaz ◽  
Suzanne Perkins ◽  
Ambar Kulshreshtha

Background and Objectives: Updated 2018 prostate cancer screening guidelines recommend informed decision-making discussions, which should include education on prostate cancer’s disproportionate impact on Black men. It is unknown whether academic family physicians follow these guidelines. Methods: Family physicians were surveyed as part of the 2020 Council of Academic Family Medicine Educational Research Alliance (CERA) survey. We used χ2 to compare physicians’ knowledge and screening practices stratified by physician age, gender, and percentage of Black patients in patient panel. We calculated logistic regressions predicting shared decision-making conversations, barriers to shared decision-making, inclusion of race in prostate cancer screening approach, and prostate-specific antigen (PSA) testing adjusted for physician age, gender, and percentage of Black patients. Results: Physicians reported engaging in shared decision-making for prostate cancer screening in half of eligible men. Only 29.2% of physicians reported routinely informing Black men of their increased prostate cancer risk. In logistic regressions, physician gender (female) and fewer Black patients in panel (<25%) were associated with lower frequency of shared decision-making with Black patients. Physician age (<40 years) was associated with not discussing race during screening discussions (OR 2.24, 95% CI 1.55–3.23). Conclusions: Most academic family physicians do not appropriately inform Black men of increased prostate cancer risk, with younger physicians less likely to discuss race than older physicians. Female physicians, and physicians who see fewer Black patients, are less likely to have shared decision-making conversations with Black patients. This suggests educational efforts for these groups are needed to address health disparities in prostate cancer.


2007 ◽  
Vol 177 (4S) ◽  
pp. 342-342
Author(s):  
Jochen Walz ◽  
Georg Salomon ◽  
Paul Perrotte ◽  
Andrea Gallina ◽  
Georg C. Hutterer ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 396-396
Author(s):  
Monique J. Roobol ◽  
Claartje Gosselaar ◽  
Fritz H. Schröder

2004 ◽  
Vol 171 (4S) ◽  
pp. 115-115
Author(s):  
Magnus Törnblom ◽  
Henry Eriksson ◽  
Stefan Franzen ◽  
Ove Gustafsson ◽  
Hans Lilja ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document